# Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression

> **NCT04872023** · NA · COMPLETED · sponsor: **Rennes University Hospital** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Blood and bone marrow sampling

## Key facts

- **NCT ID:** NCT04872023
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-29
- **Primary completion:** 2022-06-13
- **Final completion:** 2023-01-27
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04872023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04872023, "Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04872023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*